Expression of serum microRNA 30e-5p in type 2 diabetic patients with diabetic kidney disease

Type 2 diabetes (T2DM) is the most prevalent form of diabetes, and frequently associated with diabetic nephropathy, a leading contributor to chronic kidney disease (CKD). The presence of microalbuminuria serves as an early marker for diabetic kidney disease (DKD). Emerging evidence suggested that alterations in microRNA (miRNA) 30e-5p expression may be linked to T2DM progression, positioning it as a potential biomarker. This study investigated the clinical relevance of miRNA 30e-5p dysregulation by assessing its expression levels in T2DM patients with and without DKD. A total of 50 participants, including 25 T2DM patients with DKD and 25 T2DM patients without DKD, were examined. Serum miRNA 30e-5p levels were quantified using real-time polymerase chain reaction. Findings revealed a significant reduction in miRNA 30e-5p expression among patients with DKD compared to those without DKD (0.25 ± 0.26 vs. 0.89 ± 0.13, p < 0.001). In conclusion, miRNA 30e-5p dysregulation appears to contribute to DKD development in Egyptian T2DM patients, suggesting its potential as a prognostic biomarker.